血脂康对冠心病合并高脂血症患者疗效的Meta分析  

A Meta-analysis on lipid-regulation effect of Xuezhikang in patients with coronary heart disease complicating hyperlipemia

作　　者：李银花[1] 贾张蓉 江龙[1] 杨秋[1] 王绿娅[1] 

机构地区：[1]北京市心肺血管疾病研究所首都医科大学附属北京安贞医院,北京100029

出　　处：《中国循证心血管医学杂志》2014年第1期25-30,共6页Chinese Journal of Evidence-Based Cardiovascular Medicine

基　　金：国家自然科学基金项目(81271923);国家自然科学基金项目(81170810);北京市自然科学基金项目(7112022)

摘　　要：目的评价血脂康治疗冠心病合并高脂血症患者的疗效。方法计算机检索PubMed、Cochrane图书馆、EBSCO host、中国学术期刊网络出版总库(CNKI)、万方医学数据库、维普中文科技期刊全文数据库(VIP),检查时间为2013年10月之前。纳入标准为血脂康治疗高脂血症的随机对照试验。采用Revman 5.2软件进行Meta分析。系统评价血脂康对血清总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)的影响。结果共纳入19项随机对照试验,包括6229例患者。Meta分析显示,在冠心病常规治疗的基础上,血脂康组较安慰剂组TC、TG、LDL-C显著降低[(WMD=-1.15,95%CI:-1.67^-0.64,P<0.001)、(WMD=-0.51,95%CI:-0.83^-0.20,P=0.002)、(WMD=-0.99,95%CI:-1.38^-0.59,P<0.001)],HDL-C明显升高(WMD=0.21,95%CI:0.05~0.38,P=0.01);血脂康组较单纯常规治疗组TC、TG、LDL-C显著降低[(WMD=-1.19,95%CI:-1.45^-0.93,P<0.001)、(WMD=-1.19,95%CI:-1.45^-0.93,P<0.001)、(WMD=-1.00,95%CI:-1.27^-0.73,P<0.001)],HDL-C显著升高(WMD=0.17,95%CI:0.05~0.29,P=0.007)];血脂康与他汀类药物相比TC、TG、LDL-C、HDL-C差异均无统计学意义。结论在冠心病常规治疗的基础上,可有效调节血脂,与他汀类药物作用相当。Objective To review the lipid-regulation effect of Xuezhikang in patients with coronary heart disease （CHD） complicating hyperlipemia. Methods The databases of PubMed, Cochrane Library, EBSCO host, CNKI, WangFang Database and Vip Database were retrieved with computer until to Oct. 2013. The randomized controlled trials （RCT） were collected and read and extracted by two independent researches. The data was given a Meta-analysis by using Revman 5.2 software. The influences of Xuezhikang on the levels of cholesterol （TC）, triglyceride （TG）, low-density lipoprotein-cholesterol （LDL-C） and high-density lipoprotein-cholesterol （HDL-C） were reviewed systematically. Results There were totally 19 RCT included involving 6229 cases. The Meta-analysis showed that on the base of CHD routine treatment, the levels of TC, TG and LDL-C decreased significantly [（WMD=-1.15, 95%CI：-1.67--0.64, P〈0.001）, （WMD=-0.51, 95%CI：-0.83--0.20, P=0.002）, （WMD=-0.99, 95%CI： -1.38--0.59, P〈0.001）], and HDL-C level increased significantly （WMD=0.21, 95%CI： 0.05-0.38, P=0.01） in Xuezhikang group compared with placebo group. The levels of TC, TG and LDL-C decreased significantly [（WMD=-1.19, 95%CI：-1.45--0.93, P〈0.001）, （WMD=-1.19, 95%CI：-1.45--0.93, P〈0.001）, （WMD=-1.00, 95%CI：-1.27--0.73, P〈0.001）], and HDL-C level increased significantly （WMD=0.17, 95%CI：0.05-0.29, P=0.007） in Xuezhikang group compared with routine treatment group. The levels of TC, TG, LDL-C and HDL-C had no statistical significance between Xuezhikang and statins. Conclusion On the base of CHD routine treatment, Xuezhikang can regulate blood fat effectively and its effect is similar to that of statins.

关 键 词：血脂康 高脂血症 冠心病 META分析 

分 类 号：R541.4[医药卫生—心血管疾病]